Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus

Table 3 Frequencies of different cell populations in SLE patients and healthy controls

Cell population	Healthy controls (median and 95% CI) ¹	SLE patients (median and 95% CI)	P-value
CD3 ⁺ T cells	60.9 (57.8 to 63.9)	65.1 (55.7 to 64.3)	0.42
CD4 ⁺ T cells	62.1 (57.0 to 64.7)	55.2 (51.3 to 58.9)	0.06
CD4 ⁺ HLA-DR ⁺	6.5 (5.3 to 7.2)	31.3 (24.9 to 36.9)	0.001
CD8 ⁺ T cells	15.7 (14.3 to 18.8)	20.4 (18.6 to 24.0)	0.02
CD8 ⁺ HLA-DR ⁺	40.8 (39.0 to 43.2)	36.9 (33.4 to 41.5)	0.33
BDCA-1 ⁺ mDCs	0.40 (0.34 to 0.46)	0.31 (0.28 to 0.62)	0.19
BDCA-2 ⁺ pDCs	0.07 (0.07 to 0.11)	0.09 (0.09 to 0.16)	0.39
CD14 ⁺⁺ CD16 ^- monocytes	10.1 (9.6 to 13.3)	16.9 (16.0 to 25.2)	0.013
CD14 ⁺⁺ CD16 ⁺ monocytes	0.17 (0.15 to 0.27)	0.30 (0.44 to 0.81)	0.003
CD19 ⁺ B cells	5.6 (4.7 to 6.3)	5.1 (5.0 to 7.8)	0.78
CD19 ⁺ CD27 ⁺ IgD ^- CD38 ⁺ CD20 ^-	0.43 (0.35 to 0.75)	1.0 (0.8 to 3.0)	< 0.0001

¹For CD3⁺ T cells, dendritic cells, monocytes and B cells the percentage is calculated against the total leukocyte count. For all subpopulations, the percentage is calculated against the main population (for example, CD4⁺ T cells for all CD4⁺ T cell analyses).
CI, confidence interval; HLA, human leukocyte antigen; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell

ISSN: 1478-6362